Bafetinib

Drug Profile

Bafetinib

Alternative Names: BCR-ABL/Lyn Kinase Inhibitors; CNS-9; INNO-406; NS-187

Latest Information Update: 07 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Developer CytRx Corporation
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bone resorption; Brain cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 May 2014 Bafetinib is available for licensing as of 07 May 2014. http://www.cytrx.com
  • 18 Mar 2013 CytRx completes a phase I trial in Brain cancer in USA (NCT01234740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top